Mahmoud Mahmoudian, Phd, Frs Email and Phone Number
Mahmoud Mahmoudian, Phd, Frs work email
- Valid
- Valid
Mahmoud Mahmoudian, Phd, Frs personal email
Mahmoud Mahmoudian, Phd, Frs phone numbers
Chief Executive Officer, Director, PhD Scientist with operating, company building, fund raising and investment expertise driving growth strategies to develop and commercialize the next generation artificial intelligence-based vaccines, RNA, genetic and precision medicines.R&D – Chief Innovation Officer with 10 FDA approvals, $15B sales, including Adstiladrin®, the first gene therapy approved for bladder cancer and Rebyota®, the first microbiome-based treatment approved for recurring C. difficile infections (100 patents, publications).Venture Creation – launched 4 innovation hubs, set up venture fund and raised $400M in capital. Chaired science and investment committees to identify, incubate and monetize emerging modalities with unmet needs (autoimmune, infectious and rare diseases, immuno-oncology, neuroscience) – 6 exits, 80 deals (buy-sell side, in/ out-licensing) including a $3B M&A with Roivant.Exits – TxCell, Levo Therapeutics, FerGene, Genencor, Centrus and Athenix totaling over $2B.Executive Board – chaired as Chief Biotech Officer. Fellow of the Royal Society (FRS). Executive in Residence – Columbia, Princeton.Board of Directors:* Contera Pharma (2024 – Present)* Caravan Biologix (2024 – Present)* BioEclipse Therapeutics (2022 – Present)* Mid Atlantic Bio Angels (2020 – Present)* Manzara Therapeutics (2017 – 2022)* Academic Venture Exchange (2016 – 2022)* TxCell (2012 – 2018)* Annovis Bio (2012 – 2018)* NanoScan Imaging (2011 – 2017)
Summit Impact Partners
View- Employees:
- 3
-
General Partner, Chief Investment OfficerSummit Impact PartnersCambridge, Ma, Us
-
General Partner, Chief Biotech Investment OfficerSummit Impact Partners 2024 - PresentVenture Studio – innovators in catalyzing translation of the next generation nature-inspired AI-driven targeted therapies into cures to improve human health.
-
Board Of DirectorsContera Pharma 2024 - PresentRNA Therapies – artificial intelligence-based precision medicines for neurological disorders. -
Board Of Directors, Chief Corporate Development OfficerCaravan Biologix 2024 - PresentPrinceton , Nj, Usmini-CAR – the first AI-designed mini-CAR therapeutics to revolutionize cancer and hereditary disease treatment. -
Board Of Directors, Chief Operating OfficerBioeclipse Therapeutics, Inc 2022 - PresentMountain View, California, UsImmuno-oncology – the next generation AI-generated cancer medicines targeting tumor microenvironment. -
President, Chief Executive OfficerMana Therapeutic 2022 - PresentImmunotherapy – allogeneic cell therapies. -
Chief Business OfficerDynamic Cell Therapies, Inc. 2022 - PresentWatertown, Ma, UsCell Therapy – controllable CAR-T cells in solid tumors. -
Managing DirectorCobro Ventures 2022 - 2024Mclean, Virginia, UsVenture Fund – company building, venture creation and biotech investments operating across its portfolio incubating disruptive scientific breakthroughs.* AI Proteins – Chief Business Officer (mini-proteins)* MANA Therapeutic – President, CEO (cellular medicines)* Dynamic Cell Therapies – Chief Business Officer (tunable CAR-T) -
Senior Vice President, Head Of Global Oncology External InnovationSumitomo Pharma America, Inc. 2017 - 2022Marlborough, Massachusetts, UsHeaded innovation hubs worldwide – Chief Science Scout leading venture investments and external partnerships with academia, syndicating with venture capital to develop new biology, technologies and treatments in cancer including oRNA – circular RNA ($200M series B).Venture Fund – launched corporate fund as an early-stage investor. Executive Committee – chaired science and investment committees. Worked with board members, scientific advisory board, cross-functional teams (R&D, clinical, regulatory, manufacturing, commercial) to expedite discovery, development and regulatory approvals of novel modalities (RNA therapies, gene editing, artificial intelligence) including Manzara Therapeutics – generative AI.Venture Creation – raised $100M in capital to build academic and venture hubs. Established oncology research alliance with Columbia, Wistar Institute, Harvard and Dana-Farber Cancer Institute. Invested in MPM Capital oncology fund as Limited Partner – member of investor committee. Dana-Farber Innovations Research Fund – $10M investment to discover breakthrough medicines. Roivant – launched Sumitovant in a $3B acquisition (Myovant, Urovant, Enzyvant, Altavant, Spirovant). -
Vice President, Head Of Innovative MedicinesFerring Pharmaceuticals 2012 - 2017St-Prex, ChInnovation Hub – global Head reporting to President. Led scientific, commercial due diligence teams to scout, evaluate and develop novel medicines including Rebyota®, the first FDA approved microbiome-based treatment for C. difficile infections.Business Development – raised $100M in capital, formed Trizell SA to commercialize immunotherapy pipeline. Levo Therapeutics – spun off NewCo in rare diseases, raised $40M series A, sold to Acadia Pharma. Ferring Microbiome Institute – joint venture with Intralytix and Karolinska Institute to map human gut microbiota. TxCell – in-licensed OvaSave® (Crohn’s disease), developed and sold to Sangamo for $84M. Launched FerGene – developed Adstiladrin® for bladder cancer with $570M investment from Blackstone.External Research – led investments and incubation of disruptive platforms (mRNA vaccines, phage and gene therapies) for celiac disease, prostate, ovarian and pancreatic cancers including Viventia Bio – antibody drug conjugate, acquired by Eleven Biotherapeutics. -
Managing Director, Business Development & LicensingMerck 2007 - 2012Merck Bioventures – led scouting, scientific search and evaluation, licensing, venture investments in vaccines and biologics.Business Development – structured deals in immuno-oncology, autoimmune disorders and infectious diseases including acquisition of Sirna – RNA interference to aid drug discovery ($1.1B). GlycoFi – yeast glycosylation platform for antibody production ($400M). Lonza – joint venture for biomanufacture of pneumococcal vaccine (Pneumovax®).External Research – chaired governance committees that included technical transfer, manufacturing and alliance management for GMP scale up and BLA submissions. Led global development teams with multiple FDA approvals and launches – meningococcal vaccine (MenB®), human papillomavirus vaccine (Gardasil®), shingles vaccine (Zostavax®).
-
Chief Innovation Officer, Executive CommitteeDow 2004 - 2007Midland, Michigan, UsHeaded research and development across five sites (US, UK, France, China, Japan) generating $600M sales with 200 reports. Directed global teams that developed products for bio-pharmaceutical applications in emerging markets (China, India, Brazil).Innovation Hub – established biosciences footprint. Identified new technologies for joint ventures, co-development or out-licensing deals with strategic partners. Fresenius – diagnostic kits for sepsis. Sanofi – streamlining insulin production. Genzyme – ophthalmology, biodegradable polymers for targeted delivery. Millipore – development and manufacture of biologics ($100M).Executive Committee – chaired corporate growth at Rohm & Haas (reported to CEO). Member of Emerging Technology Board of Directors. Dow acquired Rohm & Haas in 2007 for $16B. -
Chief Biotechnology Officer, Board Of DirectorsEastman 2001 - 2004Kingsport, Tennessee, UsRecruited by CEO to build biotech hub. Headed global research, implemented strategies for corporate growth and diversification.Innovation Hub – developed broad pipeline, infrastructure that included strategic alliances, targeted divestitures, in/ out-licensing, acquisitions and venture investments. Athenix – $1M investment, sold to Bayer for $400M. Centrus – spun off diagnostics NewCo, sold to Neogene. Altus – acquisition, Enzyme Replacement Therapy for cystic fibrosis. Genencor – metabolic engineering, 51% equity investment, sold to Danisco for $475M.Corporate Development – chaired Biotechnology Board of Directors and investment committee. -
Executive Director, Biopharm R&DGlaxosmithkline 1988 - 2001Brentford, Middlesex, GbLed global cross-functional drug development teams (discovery, preclinical, clinical, biomanufacturing) in vaccines, biologics and small molecules. FDA approvals – hepatitis B (Lamivudine®), influenza (Relenza®), HIV (Epivir®, Abacavir®, Trizivir®), leukemia (Zygara®), shingles vaccine (Shingrix®), pneumococcal vaccine (Synflorix®).R&D – developed GMP fermentation and biological processes (microbial and mammalian cell cultures, natural products) for multi-ton scale product launches including Relenza® using immobilized recombinant aldolase with 2500 continuous enzyme reuse.External Research – chaired steering committees for key alliances (Amgen, Gilead, Vertex) in neuroscience, anti-infectives, cardiometabolic and inflammatory disorders.
Mahmoud Mahmoudian, Phd, Frs Skills
Mahmoud Mahmoudian, Phd, Frs Education Details
-
Imperial College LondonDoctor Of Philosophy (Phd). Master Of Science (Msc) -
The Wharton SchoolMarketing
Frequently Asked Questions about Mahmoud Mahmoudian, Phd, Frs
What company does Mahmoud Mahmoudian, Phd, Frs work for?
Mahmoud Mahmoudian, Phd, Frs works for Summit Impact Partners
What is Mahmoud Mahmoudian, Phd, Frs's role at the current company?
Mahmoud Mahmoudian, Phd, Frs's current role is General Partner, Chief Investment Officer.
What is Mahmoud Mahmoudian, Phd, Frs's email address?
Mahmoud Mahmoudian, Phd, Frs's email address is ma****@****rck.com
What is Mahmoud Mahmoudian, Phd, Frs's direct phone number?
Mahmoud Mahmoudian, Phd, Frs's direct phone number is +121565*****
What schools did Mahmoud Mahmoudian, Phd, Frs attend?
Mahmoud Mahmoudian, Phd, Frs attended Imperial College London, The Wharton School.
What skills is Mahmoud Mahmoudian, Phd, Frs known for?
Mahmoud Mahmoudian, Phd, Frs has skills like Business Development, Corporate Development, Research And Development, Alliance Management, Portfolio Management, Drug Development.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial